Dialysis News and Research

Latest Dialysis News and Research

3SBio fourth quarter total net revenues increase 38.2% to RMB139.9M

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced its unaudited financial results for the fourth quarter and full year ended December 31, 2011.

9 Mar 2012

3SBio, DaVita partner to offer dialysis services in NE China

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD) today announced it has entered into an agreement with 3SBio Inc., a leading Chinese biotechnology developer of biopharmaceutical products, to establish a joint venture for providing dialysis treatments in northeastern China.

9 Mar 2012

Not all patients with CKD are destined for kidney failure

Not all patients with chronic kidney disease (CKD) are destined for kidney failure, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

9 Mar 2012

Cantel second quarter net income increases 28% to $7,294,000

CANTEL MEDICAL CORP. reported a 28% increase in net income to a record $7,294,000, or $0.27 per diluted share, on a 20% increase in sales to a record $97,297,000 for the second quarter ended January 31, 2012.

8 Mar 2012

Diaverum takes an active role in 2012 World Kidney day

Diaverum, one of the world's leading renal care service providers, is taking an active role in today's World Kidney day. Through activities such as open door days at dialysis clinics, free kidney screening and blood pressure tests, Diaverum is increasing awareness for renal diseases and informing about possible prevention measures.

8 Mar 2012

Researchers identify key molecular player in mouse model of kidney disease

In findings that may lead to clinical trials of a promising new drug for kidney disease, researchers at Beth Israel Deaconess Medical Center (BIDMC) and their colleagues have identified a key molecular player and shown how a targeted experimental drug can reverse kidney damage in mouse models of diabetes, high blood pressure, genetic kidney disease, and other kidney injuries.

8 Mar 2012

AMAG fourth quarter total revenues decrease to $14.9 million

AMAG Pharmaceuticals, Inc. a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia, today reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2011. As of December 31, 2011, the company's cash, cash equivalents and investments totaled approximately $230 million.

5 Mar 2012

The Contraception Mandate is the end of individual liberty

In March 2010, the Democrat-controlled Congress forced the passage of the Patient Protection and Affordable Care Act (now known as ObamaCare) over the strong objections of the majority of Americans, most of whom were either already receiving taxpayer-funded health insurance or were satisfied with their private coverage.

5 Mar 2012

Concert commences dosing in CTP-499 Phase 2 clinical trial for diabetic nephropathy

Concert Pharmaceuticals, Inc. today announced the initiation of dosing in a Phase 2 clinical trial evaluating CTP-499, an investigational drug for the treatment of diabetic nephropathy, the leading cause of chronic kidney disease (CKD) in the US.

5 Mar 2012

RMC offers groundbreaking new procedure for LSS patients

More than one million people are diagnosed and treated each year in the United States for lumbar spinal stenosis (LSS), a condition that occurs from the narrowing of the spinal canal. Peter Staats, M.D., in conjunction with Riverview Medical Center, is offering LSS patients a groundbreaking new procedure, mild (minimally invasive spinal decompression) that safely and therapeutically reduces pain and improves mobility.

1 Mar 2012

EMA acceptance of peginesatide MAA triggers $5M milestone payment to Affymax

Affymax, Inc. today announced that it will receive a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize peginesatide.

27 Feb 2012

Diaverum expands core dialysis clinic network

Diaverum, one of the world's leading renal care service providers, added the 250th clinic to its growing clinic network throughout Europe, Latin America, Australia, and the Middle East.

27 Feb 2012

Kidney failure patients may benefit from frequent and longer dialysis treatments

Frequent and longer dialysis treatments may provide more benefits for patients than conventional dialysis treatments, according to several studies appearing in upcoming issues of the Journal of the American Society Nephrology.

24 Feb 2012

Machine perfusion offers significant improvements for 3-year graft survival in kidney transplantation

Study results published today in the New-England-Journal of Medicine show that 3-year graft survival is significantly greater in all transplanted kidneys machine perfused in the LifePort Kidney Transporter compared to those stored in a traditional box of ice. The graft survival difference at three years was most pronounced for kidneys from expanded criteria donors.

23 Feb 2012

Some diets and diet pills may cause further kidney damage in overweight adults

With 1 in 5 overweight Americans suffering from chronic kidney disease, Cleveland Clinic researchers analyzed the nutritional and lifestyle habits of overweight adults, finding that their methods included diets and diet pills that may cause further kidney damage.

22 Feb 2012

Frailty test for elderly also helps measure transplant candidates

A simple, 10-minute bedside assessment conducted prior to surgery appears to be the best method yet for predicting which kidney transplant patients will do well with their new organs, new Johns Hopkins research suggests.

21 Feb 2012

The final link in world's longest living-donor kidney transplant chain

A Loyola University Medical Center patient has become the final link in the world's longest living-donor kidney transplant chain.

20 Feb 2012

Paricalcitol does not improve clinical outcomes for patients with CKD

Patients with chronic kidney disease who received the vitamin D compound paricalcitol for up to 48 weeks did not show improvement on measures of cardiac structure, function, or left ventricular mass, compared to patients who received placebo, according to a study in the February 15 issue of JAMA.

15 Feb 2012

Canada organ donation rates plateau

A report released Monday by the Canadian Institute for Health Information reveals that public awareness campaigns and stories of grateful organ recipients have not done much to improve the number of organ donations in Canada. Donor rates have stagnated in the country since 2006 while thousands of Canadians continue to languish on wait lists for organs, the report adds.

14 Feb 2012

ALung closes $10 million Series B financing round

ALung Technologies, Inc., a leading developer of advanced respiratory products, announced today that it has closed a $10 million Series B financing round. The investment will support the continued commercialization of ALung's flagship product, the Hemolung Respiratory Assist System (RAS), which provides partial respiratory assistance to patients in acute respiratory failure.

6 Feb 2012